Eligible to anti-PD1 therapy alone or combined to anti CTLA4.
Informed consent
Age \>18 year
You may not be if
Persistent toxicity \> grade 2 (NCIC-CTCAE version 4) related to 1 regimen before switching to the other
Ocular melanoma
Active, known or suspected autoimmune disease which could be significantly worsened by immunotherapies; patients with vitiligo, type I diabetes mellitus, hypothyroidism, psoriasis non requiring systemic treatment are permitted to enroll.
HIV infection
Active Interstitial lung disease or pneumonitis
Contra-indication for tumor biopsy
No health care insurance
Clareo Health | Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma
